Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06960213 · ClinicalTrials.gov registry record · Phase 3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
A Phase 3 study of Hereditary Angioedema and HAE, sponsored by ADARx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT06960213 is a Phase 3 study of Hereditary Angioedema and HAE that is actively recruiting participants, run by ADARx Pharmaceuticals. The registered enrollment target is 90 participants, above the 69-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (30% higher). The trial reports 14 study locations across 10 states.
The verdict
NCT06960213, a Phase 3 study of Hereditary Angioedema and HAE, is actively recruiting participants, sponsored by ADARx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ADX-324
Study Locations (14)
Ohio
- ADARx Clinical Site - Cincinnati
- ADARx Clinical Site - Columbus
- ADARx Clinical Site - Toledo
Other
- ADARx Clinical Site - Hradec Králové
- ADARx Clinical Site - Budapest
- ADARx Clinical Site - Madrid
Arkansas
- ADARx Clinical Site - Little Rock
California
- ADARx Clinical Site - Walnut Creek
Maryland
- ADARx Clinical Site - Wheaton
Michigan
- ADARx Clinical Site - Detroit
Missouri
- ADARx Clinical Site - St Louis
Nevada
- ADARx Clinical Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06960213
The ClinicalTrials.gov registry entry for NCT06960213 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 69-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (30% higher). The listed sponsor is ADARx Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hereditary Angioedema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06960213 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Ohio, Other, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06960213 about?
NCT06960213 is a clinical study titled "STOP-HAE: A Phase 3 Study of ADX-324 in HAE". This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
What is the current status of trial NCT06960213?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2025-08-28. Estimated completion is 2027-12-31.
What conditions does trial NCT06960213 study?
This clinical trial studies the following conditions: Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2.
What interventions are being tested in trial NCT06960213?
The interventions under investigation include: Placebo (DRUG), ADX-324 (DRUG).
Who is sponsoring clinical trial NCT06960213?
This trial is sponsored by ADARx Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06960213 being conducted?
This trial has 14 study locations across Arkansas, California, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
COMPLETED · Phase 3
-
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.